STK11 and non-small cell lung carcinoma: In support of this conclusion, a second large, real-world study focusing on STK11 in NSCLC showed worse OS outcomes in patients with STK11 mutations (N = 328), regardless of treatment (chemotherapy or ICI therapy), versus STK11 WT metastatic NSCLC [63].